Variant Bio Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
46
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$105M
- Investors
-
9
Variant Bio General Information
Description
Developer of medical therapies intended to improve global health by studying genes and health-related traits. The company uses sequencing technology, statistical genetics, and machine learning to get insights from human genetics, which allows it to identify the basis and resistance of disease, making it an ideal match for drug discovery, enabling patients to have access to genomic drugs for unmet needs, including neurodegenerative, autoimmune, and cardiometabolic diseases.
Contact Information
Website
www.variantbio.comCorporate Office
- 1150 Eastlake Avenue East
- Suite 1000
- Seattle, WA 98109
- United States
Corporate Office
- 1150 Eastlake Avenue East
- Suite 1000
- Seattle, WA 98109
- United States
Variant Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 04-Nov-2021 | $105M | Completed | Pre-Clinical Trials | ||
| 2. Early Stage VC (Series A) | 05-Aug-2020 | Completed | Pre-Clinical Trials | |||
| 1. Seed Round | 01-Jan-2018 | $1.54M | $1.54M | Completed | Startup |
Variant Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 513,027 | $0.001000 | 8% | $3 | $3 | 1x | $3 | 3.53% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Variant Bio Comparisons
Industry
Financing
Details
Variant Bio Competitors (3)
One of Variant Bio’s 3 competitors is Decode Genetics, a Formerly VC-backed company based in Reykjavik, Iceland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Decode Genetics | Formerly VC-backed | Reykjavik, Iceland | ||||
| HiFiBiO Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA |
Variant Bio Signals
Variant Bio Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cercano Management | PE/Buyout | Minority | ||
| General Catalyst | Venture Capital | Minority | ||
| SoftBank Investment Advisers | Growth/Expansion | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Alta Partners | Venture Capital | Minority |
Variant Bio FAQs
-
When was Variant Bio founded?
Variant Bio was founded in 2018.
-
Where is Variant Bio headquartered?
Variant Bio is headquartered in Seattle, WA.
-
What is the size of Variant Bio?
Variant Bio has 46 total employees.
-
What industry is Variant Bio in?
Variant Bio’s primary industry is Drug Discovery.
-
Is Variant Bio a private or public company?
Variant Bio is a Private company.
-
What is the current valuation of Variant Bio?
The current valuation of Variant Bio is .
-
What is Variant Bio’s current revenue?
The current revenue for Variant Bio is .
-
How much funding has Variant Bio raised over time?
Variant Bio has raised $131M.
-
Who are Variant Bio’s investors?
Cercano Management, General Catalyst, SoftBank Investment Advisers, Alexandria Venture Investments, and Alta Partners are 5 of 9 investors who have invested in Variant Bio.
-
Who are Variant Bio’s competitors?
Decode Genetics, HiFiBiO Therapeutics, and Genetix Biotherapeutics are competitors of Variant Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process